Endogenous progesterone is associated to amyotrophic lateral sclerosis prognostic factors

Acta Neurologica Scandinavica

Volumn 123, Issue 1, 2011, Pages 60-67

  Gargiulo Monachelli, G ^a,b   Meyer, M ^a   Rodriguez G E ^b   Garay, L I ^a,c   Sica, R E P ^c   De Nicola, A F ^a,c   Gonzalez Deniselle M C ^a,c  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b HOSPITAL RAMOS MEJÍA   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Amyotrophic lateral sclerosis; Cortisol; Neuroprotection; Progesterone; Prognostic factors; Survival

Indexed keywords

HYDROCORTISONE; PROGESTERONE;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE COURSE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MALE; PROGNOSIS; SURVIVAL;

AMYOTROPHIC LATERAL SCLEROSIS; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PROGESTERONE; PROGNOSIS; RADIOIMMUNOASSAY; STATISTICS AS TOPIC;

EID: 78650048883     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01385.x     Document Type: Article

References (40)

1. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-91.
2. Del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, Van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003;60: 813-9.
3. Ilzecka J. Decreased serum soluble TRAIL levels in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2008;117:343-6.
4. Fiszman ML, Ricart KC, Latini A, Rodríguez G, Sica RE. In vitro neurotoxic properties and excitatory aminoacids concentration in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Relationship with the degree of certainty of disease diagnoses. Acta Neurol Scand 2010;121:120-6.
5. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004;27:723-49.
6. De Nicola AF, Labombarda F, Deniselle MC et al. Progesterone neuroprotection in traumatic CNS injury and motoneuron degeneration. Front Neuroendocrinol 2009;30:173-87.
7. González Deniselle MC, López JJ, González SL, Pietranera L, De Nicola AF. Neuroprotection in the Wobbler mouse, a genetic model of spinal cord motor neuron disease. Neurobiol Dis 2002;11:457-68.
8. Labombarda F, Gonzalez SL, González Deniselle MC et al. Progesterone increases the expression of myelin basic protein and the number of cells showing NG2 immunostaining in the lesioned spinal cord. J Neurotrauma 2006;23:181-92.
9. Roof RL, Hall ED. Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. J Neurotauma 2000;17:367-88.
10. Gibson CL, Coomber B, Rathbone J. Is progesterone a candidate neuroprotective factor for treatment following ischemic stroke? Neuroscientist 2009;15:324-32.
11. Koenig HL, Schumacher M, Ferzaz B et al. Progesterone synthesis and myelin formation by Schwann cells. Science 1995;268:1500-3.
12. Wright DW, Kellermann AL, Hertzberg VS et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 2007;49:391-402.
13. Xiao G, Wei J, Jan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury. Crit Care 2008;12:R61.
14. Stein DG. Brain damage, sex hormones and recovery: a new role for progesterone and estrogen? Trends Neurosci 2001;24:386-91.
15. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial 'Clinical limits of amyotrophic lateral sclerosis' workshop contributors. J Neurol Sci 1994;124(Suppl.):96-107.
16. Nicolau GY, Lakatua D, Sackett-Lundeen L, Haus E. Circadian and circannual rhythms of hormonal variables in elderly men and women. Chronobiol Int 1984;1:301-19.
17. Cedarbaum JM, Stambler N, Malta E et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13-21.
18. Kimura F, Fujimura C, Ishida S et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006;66:265-7.
19. Chio A, Logroscino G, Hardiman O et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2008;5:1-14.
20. Patacchioli FR, Monnazzi P, Scontrini A et al. Adrenal dysregulation in amyotrophic lateral sclerosis. J Endocrinol Invest 2003;26:RC23-5.
21. Bernardi F, Lanzone A, Cento RM et al. Allopregnanolone and dehydroepiandrosterone response to corticotrophin releasing factor in patients suffering from Alzheimer's disease and vascular dementia. Eur J Endocrinol 2000;142:466-71.
22. Aziz NA, Pijl H, Frölich M, Van Der Graaf AW, Roelfsema F, Roos RA. Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. J Clin Endocrinol Metab 2009;94:1223-8.
23. De Kloet ER. Hormones and the stressed brain. Ann N Y Acad Sci 2004;1018:1-15.
24. Takeda T, Uchihara T, Arai N, Mizutani T, Iwata M. Progression of hippocampal degeneration in amyotrophic lateral sclerosis with or without memory impairment: distinction from Alzheimer disease. Acta Neuropathol 2009;117:35-44.
25. Resko JA. Endocrine control of adrenal progesterone secretion in the ovariectomized rat. Science 1969;164:70-1.
26. Elman I, Breier A. Effects of acute metabolic stress on plasma progesterone and testosterone in male subjects: relationship to pituitary-adrenocortical axis activation. Life Sci 1997;61:1705-12.
27. Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002;57:257-75.
28. Baulieu EE. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Rec Progr Horm Res 1997;52:1-31.
29. Labombarda F, Pianos A, Liere P et al. Injury elicited increase in spinal cord neurosteroid content analyzed by gas chromatography mass spectrometry. Endocrinology 2006;147:1847-59.
30. Bixo M, Andersson A, Winblad B, Purdy RH, Bäckström T. Progesterone, 5α-pregnane-3, 20-dione and 3α-hydroxy-5α-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res 1997;764:173-8.
31. Weill-Engerer S, David JP, Sazdovitch V et al. Neuro-steroid quantification in human brain regions: comparison between Alzheimer's and non-demented patients. J Clin Endocrinol Metab 2002;87:5138-43.
32. Gonzalez Deniselle MC, Gonzalez S, Piroli G, Ferrini M, Lima AE, De Nicola AF. Glucocorticoid receptors and actions in the spinal cord of the wobbler mouse, a model for neurodegenerative diseases. J Steroid Biochem Molec Biol 1997;60:205-13.
33. Gonzalez Deniselle MC, Gonzalez SL, Piroli GG, Lima AE, De Nicola AF. The 21-aminosteroid U-74389F increases the number of glial fibrillary acidic protein-expressing astrocytes in the spinal cord of control and Wobbler mice. Cell Mol Neurobiol 1996;6:61-72.
34. Genazzani AR, Petraglia F, Bernardi F et al. Circulating levels of Allopregnanolone in humans: gender, age and endocrine influences. J Clin Endocrinol Metab 1998;83:2099-103.
35. Singh M. Mechanisms of progesterone-induced neuroprotection. Ann N Y Acad Sci 2005;1052:145-51.
36. Mandrioli J, Faglioni P, Nichelli P, Sola P. Amyotrophic lateral sclerosis: prognostic indicators of survival. Amyotroph Lateral Scler 2006;7:211-20.
37. Dupuis L, Corcia P, Fergani A et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008;70:1004-9.
38. Gonzalez Deniselle MC, Garay L, Gonzalez S et al. Progesterone modulates brain-derived neurotrophic factor and choline acetyltransferase in degenerating Wobbler motoneurons. Exp Neurol 2007;203:406-14.
39. Gonzalez Deniselle MC, Garay L, Gonzalez S, Guennoun R, Schumacher M, De Nicola AF. Progesterone restores retrograde labeling of cervical motoneurons in Wobbler mouse motoneuron disease. Exp Neurol 2005;195:518-23.
40. De Nicola AF, Labombarda F, Gonzalez SL, Gonzalez Deniselle MC, Guennoun R, Schumacher M. Steroid effects on glial cells: detrimental or protective for spinal cord function? Ann N Y Acad Sci 2003;1007:317-28.